ClinicalTrials.gg
CompletedNCT01658839Updated Apr 1, 2016Results posted

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

A Phase 1 interventional study of Travoprost ophthalmic solution, 0.004% (new formulation) in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 2 Months to 17 Years. Per ClinicalTrials.gov, last updated 2016-04-01.

Sponsored by Alcon Research (part of Alcon) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
2 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Glaucoma by Alcon — none open to participants now, none under way, none of them phase 3. Glaucoma · Alcon.

Enrollment
73rd of 77
25 · median 112
Started
2013
with 5 others
Phase 1
Only one
of the 93
Registered
72nd of 93
by date

Among the 93 studies in Glaucoma by Alcon, this one is the 73rd largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2013, is the only one in phase 1, and was the 72nd registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 93 studies in Glaucoma by Alcon is open now. The open studies under Glaucoma, anywhere →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 2 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 93 studies in Glaucoma by Alcon as a file.
02

Study summary

The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Keywords

  • pediatric glaucoma
  • pediatric ocular hypertension
  • travoprost
04

Who can participate

Ages eligible
2 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of glaucoma or ocular hypertension in at least 1 eye.
  • Parent/legal guardian must provide , and children must agree to sign an approved assent form when applicable.
  • Must agree to comply with the requirements of the study and must be accompanied by a parent/guardian.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Females of that are currently pregnant, have a positive result on a pregnancy test at the Screening Visit, intend to become pregnant during the study period, are breast feeding, or are not using measures.
  • One sighted eye or monocular, including patients who cannot be dosed in both eyes for any reason.
  • History of chronic, recurrent or severe inflammatory eye disease.
  • Ocular trauma requiring medical attention within the past 3 months prior to the Screening Visit.
  • Ocular infection or ocular inflammation within the past 30 days prior to the Screening Visit.
  • or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment.
  • Other severe ocular pathology (including severe dry eye), that in the opinion of the Investigator, would preclude the administration of a topical prostaglandin analogue.
  • Intraocular surgery within the past 30 days prior to the Screening Visit.
  • Any abnormality preventing reliable tonometry.
  • Any other conditions including severe illness which would make the patient, in the opinion of the Investigator, unsuitable for the study.
  • to prostaglandin analogues or to any component of the study medications in the opinion of the Investigator.
  • Therapy with another agent or device within 30 days prior to the Screening Visit.
  • Body weight \< 5kg.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Travoprost

    Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days

    Drug: Travoprost ophthalmic solution, 0.004% (new formulation)

Interventions

  • DrugTravoprost ophthalmic solution, 0.004% (new formulation)

    Travoprost ophthalmic solution, 0.004%, new formulation

06

What researchers measure

Primary outcomes

  1. Maximum Observed Travoprost Free Acid Plasma Concentration (Cmax)

    Travoprost free acid plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). Cmax was calculated for each participant with at least 1 quantifiable time point.

    Time frame: Day 7, Up to 80 minutes postdose

  2. Time to Reach Cmax (Tmax)

    Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). Tmax was calculated for each participant with at least 1 quantifiable time point.

    Time frame: Day 7, Up to 80 minutes postdose

  3. Time to Last Measurable Concentration (Tlast)

    Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). Tlast was calculated for each participant with at least 1 quantifiable time point.

    Time frame: Day 7, Up to 80 minutes postdose

  4. Area Under the Analyte Plasma Concentration-time Curve to the Last Quantifiable Sampling Time Point [AUC(0-tlast)]

    Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). AUC(0-tlast) was calculated for each participant with at least 2 quantifiable time points.

    Time frame: Day 7, Up to 80 minutes postdose

  5. Area Under the Analyte Plasma Concentration-time Curve Over the Dosing Interval (Inf)[AUC(0-∞)]

    Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). AUC(0-∞) was calculated for each participant with at least 3 quantifiable time points.

    Time frame: Day 7, Up to 80 minutes postdose

  6. Half-life (t½)

    Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). T½ was calculated for each participant with at least 3 quantifiable time points.

    Time frame: Day 7, Up to 80 minutes postdose

07

Results

Posted Jul 21, 2014

Participant flow

Participants were recruited from 4 investigational centers located in the US, 1 located in France, 1 located in Spain, and 1 located in Saudi Arabia.

Participant flow — Overall Study
MilestoneTravoprost
Started25
Completed25
Not completed0

Outcome measures

PrimaryMaximum Observed Travoprost Free Acid Plasma Concentration (Cmax)

Travoprost free acid plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). Cmax was calculated for each participant with at least 1 quantifiable time point.

Time frame:
Day 7, Up to 80 minutes postdose
Reported as:
Mean · ng/mL
Maximum Observed Travoprost Free Acid Plasma Concentration (Cmax)
ng/mLTravoprost
Overall (n=11)0.0256 ± 0.0158
2 mo to < 3 years (n=2)0.0471 ± 0.0105
3 to <12 years (n=6)0.0258 ± 0.0128
12 to <18 years (n=3)0.0109 ± 0.000046
PrimaryTime to Reach Cmax (Tmax)

Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). Tmax was calculated for each participant with at least 1 quantifiable time point.

Time frame:
Day 7, Up to 80 minutes postdose
Reported as:
Mean · hours
Time to Reach Cmax (Tmax)
hoursTravoprost
Overall (n=11)0.25 ± 0.15
2 mo to <3 years (n=2)0.26 ± 0.11
3 to <12 years (n=6)0.17 ± 0.00
12 to <18 years (n=3)0.39 ± 0.26
PrimaryTime to Last Measurable Concentration (Tlast)

Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). Tlast was calculated for each participant with at least 1 quantifiable time point.

Time frame:
Day 7, Up to 80 minutes postdose
Reported as:
Mean · hours
Time to Last Measurable Concentration (Tlast)
hoursTravoprost
Overall (n=11)0.42 ± 0.35
2 mo to <3 years (n=2)0.34 ± 0.01
3 to <12 years (n=6)0.46 ± 0.47
12 to <18 years (n=3)0.39 ± 0.26
PrimaryArea Under the Analyte Plasma Concentration-time Curve to the Last Quantifiable Sampling Time Point [AUC(0-tlast)]

Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). AUC(0-tlast) was calculated for each participant with at least 2 quantifiable time points.

Time frame:
Day 7, Up to 80 minutes postdose
Reported as:
Mean · ng*hr/mL
Area Under the Analyte Plasma Concentration-time Curve to the Last Quantifiable Sampling Time Point [AUC(0-tlast)]
ng*hr/mLTravoprost
Overall (n=6)0.0116 ± 0.0099
2 mo to <3 years (n=2)0.0101 ± 0.0014
3 to <12 years (n=4)0.0123 ± 0.0127
PrimaryArea Under the Analyte Plasma Concentration-time Curve Over the Dosing Interval (Inf)[AUC(0-∞)]

Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). AUC(0-∞) was calculated for each participant with at least 3 quantifiable time points.

Time frame:
Day 7, Up to 80 minutes postdose
Reported as:
Mean · ng*hr/mL
Area Under the Analyte Plasma Concentration-time Curve Over the Dosing Interval (Inf)[AUC(0-∞)]
ng*hr/mLTravoprost
Overall (n=1)0.0389 ± NA
3 to <12 years (n=1)0.0389 ± NA
PrimaryHalf-life (t½)

Analyte plasma concentrations at each collection time point (predose, 10, 20, 40, 80 minutes postdose) were quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS). T½ was calculated for each participant with at least 3 quantifiable time points.

Time frame:
Day 7, Up to 80 minutes postdose
Reported as:
Mean · hours
Half-life (t½)
hoursTravoprost
Overall (n=1)0.53 ± NA
3 to <12 years (n=1)0.53 ± NA

Adverse events

Collected over Adverse events (AEs) were collected for the duration of the study (6 months). This analysis group includes all participants who received study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travoprost—1/25 (4%)0/25 (0%)
Most frequent serious events
Most frequent serious events
EventTravoprost
TrabeculectomySurgical and medical procedures1/25

Baseline characteristics

This analysis population includes all enrolled participants.

Age, Continuous
Age, Continuous(years)Travoprost
Mean9.9 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)Travoprost
Female12
Male13
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2012
First posted
Aug 7, 2012
Start
Jan 2013
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Jul 21, 2014
Last update
Apr 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01658839
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Aug 7, 2012
Start date
Jan 2013
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Jul 21, 2014
Last update
Apr 1, 2016

Study contacts

Subha Venkataraman
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion